Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
The follow-up pivotal trial (METAOD006 / OPTIONS) enrolled a larger cohort and failed to replicate statistically significant weight loss, which led Metabolic Pharmaceuticals to halt the formal drug development program in 2007
Genetic polymorphisms in GSTs, particularly the GSTM1 and GSTT1 null genotypes, significantly influence SFNs metabolic fate and clinical efficacy
Accelerated Healing and Recovery One of BPC-157s most well-known benefits is its ability to speed up the healing process for injuries, particularly in the muscles, tendons, and ligaments
This trial established proof of concept that amylin receptor agonism alone could produce clinically meaningful weight loss
US$ 24.91
US$ 20.46
US$ 26.87
US$ 28.23
US$ 25.68
US$ 29.31
